BiotechTube

BHQ880

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smoldering Multiple Myeloma

Conditions

Smoldering Multiple Myeloma

Trial Timeline

May 1, 2011 → Nov 1, 2013

NCT ID
NCT01302886

About BHQ880

BHQ880 is a phase 2 stage product being developed by Novartis for Smoldering Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT01302886. Target conditions include Smoldering Multiple Myeloma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01302886Phase 2Completed

Competing Products

13 competing products in Smoldering Multiple Myeloma

See all competitors
ProductCompanyStageHype Score
Elotuzumab (BMS-901608; HuLuc63)AbbViePhase 2
52
carfilzomib + Lenalidomide + Dexamethasone + MelphalanAmgenPhase 2
51
DenosumabAmgenPhase 2
51
Carfilzomib + Lenalidomide + Daratumumab + DexamethasoneAmgenPhase 2
51
ElranatamabPfizerPhase 2
51
Nivolumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
51
Elotuzumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
51
Dexamethasone + Iberdomide HydrochlorideBristol Myers SquibbPhase 2
51
LinvoseltamabRegeneron PharmaceuticalsPhase 2
51
Linvoseltamab + DaratumumabRegeneron PharmaceuticalsPhase 3
76
SelinexorKaryopharm TherapeuticsPhase 2
44
IPH2101Innate PharmaPhase 2
44
PD-L1 peptideIO BiotechPhase 2
44

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85